CN107074924A - 基于突变蛋白β淀粉样蛋白(Aβ)氨基酸序列的免疫原性产物及其用途 - Google Patents

基于突变蛋白β淀粉样蛋白(Aβ)氨基酸序列的免疫原性产物及其用途 Download PDF

Info

Publication number
CN107074924A
CN107074924A CN201580047718.9A CN201580047718A CN107074924A CN 107074924 A CN107074924 A CN 107074924A CN 201580047718 A CN201580047718 A CN 201580047718A CN 107074924 A CN107074924 A CN 107074924A
Authority
CN
China
Prior art keywords
product
amino acid
antibody
proline
tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580047718.9A
Other languages
English (en)
Chinese (zh)
Inventor
S.巴格霍恩
H.希伦
A.施特赖宾格
S.吉艾西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Deutschland GmbH and Co KG
Original Assignee
AbbVie Deutschland GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Deutschland GmbH and Co KG filed Critical AbbVie Deutschland GmbH and Co KG
Publication of CN107074924A publication Critical patent/CN107074924A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
CN201580047718.9A 2014-07-07 2015-07-06 基于突变蛋白β淀粉样蛋白(Aβ)氨基酸序列的免疫原性产物及其用途 Pending CN107074924A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462021308P 2014-07-07 2014-07-07
US62/021308 2014-07-07
PCT/EP2015/065362 WO2016005328A2 (en) 2014-07-07 2015-07-06 IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF

Publications (1)

Publication Number Publication Date
CN107074924A true CN107074924A (zh) 2017-08-18

Family

ID=53525183

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580047718.9A Pending CN107074924A (zh) 2014-07-07 2015-07-06 基于突变蛋白β淀粉样蛋白(Aβ)氨基酸序列的免疫原性产物及其用途

Country Status (11)

Country Link
US (2) US20160000891A1 (enExample)
EP (1) EP3166969A2 (enExample)
JP (3) JP2017532289A (enExample)
CN (1) CN107074924A (enExample)
AU (2) AU2015286824A1 (enExample)
CA (1) CA2954031A1 (enExample)
IL (1) IL249925B (enExample)
MX (1) MX2017000094A (enExample)
RU (1) RU2750268C2 (enExample)
SG (1) SG11201700071WA (enExample)
WO (1) WO2016005328A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110412294A (zh) * 2019-08-07 2019-11-05 深圳市新产业生物医学工程股份有限公司 蛋白稳定液、蛋白校准品、试剂盒及检测蛋白准品稳定性的方法
CN112851786A (zh) * 2019-11-12 2021-05-28 深圳市新产业生物医学工程股份有限公司 可溶性的Aβ1-42变体、Aβ1-42校准品及试剂盒
CN117700525A (zh) * 2024-02-05 2024-03-15 上海良润生物医药科技有限公司 一种多肽改造体及其应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
MX336196B (es) * 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
CN107074924A (zh) * 2014-07-07 2017-08-18 艾伯维德国有限责任两合公司 基于突变蛋白β淀粉样蛋白(Aβ)氨基酸序列的免疫原性产物及其用途
WO2018047792A1 (ja) * 2016-09-06 2018-03-15 富士レビオ株式会社 サイログロブリンの測定方法及び測定試薬
US11802867B2 (en) 2016-09-13 2023-10-31 Fujirebio Inc. Cardiac troponin assay method and assay reagent
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
CN111793131A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中pf4含量的抗体对及其用途
EP4286405A4 (en) * 2021-01-28 2025-03-19 Abrain GENE THERAPY FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP4230645A1 (en) * 2022-02-22 2023-08-23 Technische Universität München Peptidic inhibitors of amyloid self- and cross-assembly
CN117586370A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007062852A2 (en) * 2005-11-30 2007-06-07 Abbott Laboratories ANTI-Aβ GLOBULOMER ANTIBODIES, ANTIGEN-BINDING MOIETIES THEREOF, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCING SAID ANTIBODIES, COMPOSITIONS COMPRISING SAID ANTIBODIES, USES OF SAID ANTIBODIES AND METHODS OF USING SAID ANTIBODIES
CN102203124A (zh) * 2008-07-25 2011-09-28 雅培制药有限公司 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途
WO2011130377A2 (en) * 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
WO2012024187A1 (en) * 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CN107074924A (zh) * 2014-07-07 2017-08-18 艾伯维德国有限责任两合公司 基于突变蛋白β淀粉样蛋白(Aβ)氨基酸序列的免疫原性产物及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007062852A2 (en) * 2005-11-30 2007-06-07 Abbott Laboratories ANTI-Aβ GLOBULOMER ANTIBODIES, ANTIGEN-BINDING MOIETIES THEREOF, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCING SAID ANTIBODIES, COMPOSITIONS COMPRISING SAID ANTIBODIES, USES OF SAID ANTIBODIES AND METHODS OF USING SAID ANTIBODIES
CN102203124A (zh) * 2008-07-25 2011-09-28 雅培制药有限公司 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途
WO2011130377A2 (en) * 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
WO2012024187A1 (en) * 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110412294A (zh) * 2019-08-07 2019-11-05 深圳市新产业生物医学工程股份有限公司 蛋白稳定液、蛋白校准品、试剂盒及检测蛋白准品稳定性的方法
CN112851786A (zh) * 2019-11-12 2021-05-28 深圳市新产业生物医学工程股份有限公司 可溶性的Aβ1-42变体、Aβ1-42校准品及试剂盒
CN112851786B (zh) * 2019-11-12 2022-11-15 深圳市新产业生物医学工程股份有限公司 可溶性的Aβ1-42变体、Aβ1-42校准品及试剂盒
CN117700525A (zh) * 2024-02-05 2024-03-15 上海良润生物医药科技有限公司 一种多肽改造体及其应用

Also Published As

Publication number Publication date
AU2015286824A1 (en) 2017-02-09
IL249925A0 (en) 2017-03-30
RU2017103527A (ru) 2018-08-07
JP2017532289A (ja) 2017-11-02
WO2016005328A2 (en) 2016-01-14
US20160000891A1 (en) 2016-01-07
JP2021001203A (ja) 2021-01-07
BR112017000428A2 (pt) 2017-10-31
CA2954031A1 (en) 2016-01-14
RU2750268C2 (ru) 2021-06-25
MX2017000094A (es) 2017-04-27
WO2016005328A3 (en) 2016-05-26
US20240075114A1 (en) 2024-03-07
SG11201700071WA (en) 2017-02-27
JP2023036606A (ja) 2023-03-14
IL249925B (en) 2021-09-30
RU2017103527A3 (enExample) 2019-02-19
EP3166969A2 (en) 2017-05-17
AU2021200575A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
US20240075114A1 (en) IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID beta (Abeta) AMINO ACID SEQUENCES AND USES THEREOF
CN102933601B (zh) β淀粉样蛋白结合蛋白
TWI705975B (zh) 抗－N3pGlu類澱粉β肽抗體及其用途
CN105348387B (zh) β淀粉样蛋白结合蛋白
JP2024075584A (ja) アミロイドベータタンパク質に対するモノクローナル抗体及びその使用
EP2542571B1 (en) Oligomer-specific amyloid beta epitope and antibodies
US20100173828A1 (en) Aß(X - 38 .. 43) oligomers, and processes, compositions, and uses thereof
CN107074925B (zh) 用于预防和/或治疗亨廷顿氏病的物质和方法
EP3166660B1 (en) Substances and methods for the use in prevention and/or treatment in huntington's disease
BR112017000428B1 (pt) Produto imunogênico com base em sequências de aminoácidos muteína amiloide beta, composição compreendendo o produto e uso do mesmo para tratar ou prevenir amiloidose
MX2008007006A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos
HK1185350B (en) Oligomer-specific amyloid beta epitope and antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination